Biopharmaceutical company Astria Therapeutics Inc (NASDAQ: ATXS) announced on Monday that it has been granted Orphan Drug Designation by the U.S. FDA for navenibart (STAR-0215), its monoclonal antibody inhibitor of plasma kallikrein, aimed at treating hereditary angioedema (HAE).
Navenibart is designed to prevent HAE attacks through long-acting administration.
Early results from the Phase 1b/2 ALPHA-STAR trial showed a 90-96% reduction in monthly attack rates with once or twice dosing over six months.
The FDA's Orphan Drug program supports therapies targeting rare diseases, providing development incentives to sponsors.
Navenibart also holds Fast Track Designation, positioning it for rapid regulatory progress.
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Cosmo and Glenmark receive European marketing authorisation for Winlevi
Polarean expands XENOVIEW 3T Coil access with Philips compatibility
Ascletis selects ASC37 oral tablets as clinical development candidate
Medivir granted FDA orphan drug designation for MIV-711 in osteogenesis imperfecta
Novo Nordisk submits sNDA to FDA for for higher semaglutide injection dose
GE HealthCare receives FDA clearance for AI-powered Pristina Recon DL mammography system
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance